10/01/2015
Anna P. Kotsia, MD, PhD; Georgios Christopoulos, MD; James A. de Lemos, MD; Darren K. McGuire, MD, MHSc; Emmanouil S. Brilakis, MD, PhD, FACC, FAHA, FESC, FSCAI; Milton Packer, MD; Subhash Banerjee, MD, FSCAI; Daisha J. Cipher, PhD, MD; Michele Roesle, RN, BSN, MD; Bavana V. Rangan, BDS, MPH, MD; Ameka Coleman, MS, BS
Intermediate SVG lesions have high rates of progression. The purpose of this study was to examine the impact of extended-release niacin (ER-niacin) vs. placebo on intermediate saphenous vein graft (SVG) lesions.
Intermediate SVG lesions have high rates of progression. The purpose of this study was to examine the impact of extended-release niacin (ER-niacin) vs. placebo on intermediate saphenous vein graft (SVG) lesions.
Intermediate SVG lesions have...